At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
Calcium Dobesilate +1 moredrug
Likely dose
Calcium Dobesilate 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Double-blind, Monocenter, Phase II Trial to Assess the Efficacy of Calcium Dobesilate (CaD) vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.
In Brief
A Phase 2 clinical trial evaluating Calcium Dobesilate and Mannitol for COVID-19 Virus Disease. Completed, enrolled 74 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of CaD in reducing SARS-CoV-2 viral load in non-hospitalized adult patients diagnosed with COVID-19, documented with a positive SARS-CoV-2 PCR and with the occurrence of COVID-19 symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Virus Disease
CountriesSwitzerland
CollaboratorsOM Pharma SA
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMay 2022
Primary CompletionNov 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedMar 31, 2022
Enrollment StartMay 17, 2022
Primary CompletionNov 10, 2023
Study CompletionFeb 5, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.3 years ago
Interventions
Calcium Dobesilatedrug
The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
Mannitoldrug
The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.